Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.41 |
| ▸ | NPY1R | P25929 | 9/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.41 |
| ▸ | NPY2R | P49146 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435145 | 0.88 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL9452736 | 0.88 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL30302903 | 0.83 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSMN1; SMN2 | |
| SCHEMBL29536042 | 0.83 | GNPAT (0.44) | NPY4RNPY1RNPY5RNPY2RFURIN | |
| SCHEMBL29375093 | 0.83 | TFPI (0.40) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL18264761 | 0.83 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL5598740 | 0.83 | NMT2 (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31064825 | 0.82 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL22618583 | 0.82 | NPY4R (0.40) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30423373 | 0.81 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | claimed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | disclosed |
| CN-106456698-B | Synthesis of beta-arrestin effectors | 特维娜有限公司 | 2022-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | NPY4R 3506/4885NPY1R 3096/4885NPY5R 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.